Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.
Antineoplastic Agents
/ therapeutic use
Betaxolol
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Case-Control Studies
Cohort Studies
ErbB Receptors
Humans
Lung Neoplasms
/ drug therapy
Mutation
Neoplasm Recurrence, Local
Paronychia
/ chemically induced
Protein Kinase Inhibitors
/ adverse effects
Retrospective Studies
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
03
2020
revised:
03
06
2020
accepted:
14
07
2020
pubmed:
26
9
2020
medline:
22
6
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
High rates of posttreatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion resulting from epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)-induced paronychia, which may even interrupt the course of treatment for EGFR-TKI therapy. Thus, we conducted this study to determine how effectively a topical β-blocker, betaxolol, prevents EGFR-TKI-induced paronychia. This case-control cohort study included a total of 131 non-small-cell lung cancer patients. The prevention group comprised 40 patients treated with topical betaxolol 0.25% solution to prevent paronychia while they received EGFR-TKI therapy. The control group comprised 91 patients who did not preventively use topical betaxolol 0.25% solution while receiving EGFR-TKI therapy. The patients' age, gender, antineoplastic regimen, duration of antineoplastic treatment before the appearance of lesions, number of involved digits (fingernails or toenails) with lesions, grading of paronychia, and pain score were recorded. In terms of the cumulative incidence of paronychia, significant differences (P < 0.01) were noted at both the 2nd and 3rd months after starting EGFR-TKIs. Furthermore, the average visual analogue scale scores were 3.125 and 6.29 in the prevention group and control group, respectively (P < 0.01). The average grades of paronychia were 1.5 and 2.12 in the prevention group and control group, respectively (P < 0.01). The average numbers of involved digits were 2.25 (range: 1-5 digits) in the prevention group and 3.03 (range: 1-7) in the control group (P = 0.07). Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia.
Sections du résumé
BACKGROUND
BACKGROUND
High rates of posttreatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion resulting from epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)-induced paronychia, which may even interrupt the course of treatment for EGFR-TKI therapy. Thus, we conducted this study to determine how effectively a topical β-blocker, betaxolol, prevents EGFR-TKI-induced paronychia.
METHODS
METHODS
This case-control cohort study included a total of 131 non-small-cell lung cancer patients. The prevention group comprised 40 patients treated with topical betaxolol 0.25% solution to prevent paronychia while they received EGFR-TKI therapy. The control group comprised 91 patients who did not preventively use topical betaxolol 0.25% solution while receiving EGFR-TKI therapy. The patients' age, gender, antineoplastic regimen, duration of antineoplastic treatment before the appearance of lesions, number of involved digits (fingernails or toenails) with lesions, grading of paronychia, and pain score were recorded.
RESULTS
RESULTS
In terms of the cumulative incidence of paronychia, significant differences (P < 0.01) were noted at both the 2nd and 3rd months after starting EGFR-TKIs. Furthermore, the average visual analogue scale scores were 3.125 and 6.29 in the prevention group and control group, respectively (P < 0.01). The average grades of paronychia were 1.5 and 2.12 in the prevention group and control group, respectively (P < 0.01). The average numbers of involved digits were 2.25 (range: 1-5 digits) in the prevention group and 3.03 (range: 1-7) in the control group (P = 0.07).
CONCLUSIONS
CONCLUSIONS
Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia.
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Betaxolol
O0ZR1R6RZ2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-184Subventions
Organisme : Chang Gung Memorial Hospital
ID : CIRPD1D0032
Organisme : Chang Gung Memorial Hospital
ID : CMRPGBI0011-3
Organisme : Ministry of Science and Technology, Taiwan
ID : NMRPD1G1171
Organisme : Ministry of Science and Technology, Taiwan
ID : NMRPD1H1031
Informations de copyright
© 2020 the International Society of Dermatology.
Références
Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50: 129-146.
Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012; 67: 400-408.
Imai H, Kaira K, Suzuki K, et al. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer 2018; 126: 41-47.
Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs 2015; 75: 1335-1348.
Yen CF, Hsu CK, Lu CW. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2018; 78: e143-e144.
Yen CF, Hsu CK, Yang HS, et al. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. Int J Dermatol 2020; 59: 326-332.
Melosky B, Leighl NB, Rothenstein J, et al. Management of EGFR TKI-induced dermatologic adverse events. Curr Oncol 2015; 22: 123-132.
Yen CF, Lee YY. Nail braces for severe paronychia induced by epidermal growth factor receptor inhibitors: an alternative to nail extraction. J Am Acad Dermatol 2018; 78: e89-e90.
Melchionna R, Bellavia G, Romani M, et al. C/EBP gamma regulates wound repair and EGF receptor signaling. J Invest Dermatol 2012; 132: 1908-1917.
Lacouture ME, Schadendorf D, Chu CY, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013; 13: 721-728.
Chu CY, Chen KY, Chang JWC, et al. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc 2017; 116: 413-423.